-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:BFH公布了强劲的2026财年第一季度业绩,每股收益(EPS)为4.15美元,同比增长50%,超出市场预期0.99美元;营收增长5%至10.2亿美元,高于华尔街预期的9.97亿美元。业绩增长主要得益于定价优化、融资成本降低以及信贷销售额强劲增长(增长7%至65亿美元,连续第六个季度实现增长)。我们认为,贷款增长的恢复是一个关键的转折点,在经历了几个季度的下滑后,期末贷款额增长2%至181亿美元,这主要得益于新合作伙伴的加入以及年轻群体购物活动的增加。资产负债表优化措施包括通过1.5亿美元的股票回购和上限期权解除,注销了350万股(占流通股的8%),并增加了6亿美元的授权额度。信贷质量趋势依然令人瞩目,违约率下降 34 个基点至 5.59%,净损失率改善 83 个基点至 7.33%,同时 CET1 比率增强至 13.3%,每股有形账面价值增长 26% 至 61.57 美元。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.